New Zealand Purchases 10.7 Million Vaccine Doses

New Zealand's government has signed an Advance Purchase Agreement with Novavax, Inc. to purchase 10.7 million doses of NVX-CoV2373, Novavax’s experimental vaccine against COVID-19. Under the terms of the agreement, Novavax will target delivering initial vaccine doses by mid-2021.

Stanley C. Erck, CEO of Novavax, stated in a press release: “We appreciate the confidence of the government of New Zealand and are pleased to contribute to ensuring that New Zealanders will have access to a protein-based vaccine through standard distribution channels, should it receive regulatory approval.”